• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
 EuroBioForum 2013 - Day 2 | Mark Poznansky

EuroBioForum 2013 - Day 2 | Mark Poznansky



EuroBioForum 2013 2nd Annual Conference ...

EuroBioForum 2013 2nd Annual Conference
27-28 May 2013 - Hilton Munich City, Munich, Germany



Ontario Genomics Institute, Canada:
Innovative Research, Innovative Translation

Dr Mark Poznansky
President and CEO Ontario Genomics Institute





Total Views
Views on SlideShare
Embed Views



1 Embed 1

http://www.eurobioforum.eu 1


Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
Post Comment
Edit your comment

     EuroBioForum 2013 - Day 2 | Mark Poznansky EuroBioForum 2013 - Day 2 | Mark Poznansky Presentation Transcript

    • Ontario’s Perspective onPersonalized Medicine:Innovative Research, Innovative TranslationDr. Mark PoznanskyOntario Genomics Institute
    • 2Ontario Genomics Institute• Driver and catalyst for the life sciences industry inOntario• Integrated approach, science and business expertise,experience brokering relationships and supportingresearch through to commercialization• Business development – 18 companies; attracted$42 million in venture capital• Research - 65 projects; total funding of $800 million; including economic,ethical, legal, environmental, social aspects• Not-for-profit corporation supported by the federaland provincial governments
    • Ontario, Canada313.5M population$71.8B in health expenditures158 hospitals25 research/academic hospitals,employing 10,000 researchers44 universities/collegesAmong the largestsingle-payer HMOs$1.9B/yr on health-related R&DToronto hasCanada’s largest concentrationof scientific research and is in thetop three bioscience clusters inNorth America
    • Life and Health R&DOntarioHealthResearch1.9B/yrHealth Charities• Heart and StrokeFoundation• Canadian CancerSocietyFederal• Canadian Institutes of Health Research• Canadian Foundation for Innovation• National Research Council• Natural Sciences and EngineeringResearch Council• Genome Canada• Tax creditsProvincial• Ontario Research Fund• Ontario Centres of Excellence• MaRS• Ontario Inst. for Cancer Research• Ontario Brain Institute• Provincial match of federal grants• Tax creditsPrivate Funding• Industrial• Venture financing• Institutional4
    • Ontario Funding:Human Genomics Research~$190M/year in federal operating funding:• Genome Canada – $915M over lifetime of GC plus over $900M inco-funding from other organizations• Genomics and personalized health competition - 4 projects• CIHR, others~$130+M/year in provincial operating funding:• Ontario Research Fund – Research Excellence: ~$165M to genomicssince 2007• Ontario Institute for Cancer Research: $82M/yr• Ontario Brain Institute: $20M/yr• Excludes matching funding5
    • Unique Initiatives inPersonalized Medicine6
    • Rheumatoid Arthritis Pilot StudyCanada (2010): $10.2B in direct health care costs$17.3B in indirect (wage-basedproductivity) costsTotal economic burden $27.5B7RA = rheumatoid arthritisPS = psoriasisIBD = inflammatory bowel diseaseSLE = systemic lupus erythematosus
    • Rheumatoid Arthritis Pilot Study• Dr. Katherine Siminovitch – Mt.Sinai,Toronto1.Discover genes via targeted andwhole exome sequencing that:• Confer risk for rheumatoid arthritis• Modulate outcome/drug response2.Develop informatics solution to:• Collect, store & mine clinical data• Integrate clinical & genomics data• Apply genomics data in the clinic to improvehealthcare delivery8ControlsCases100,000 - 1 millionmarkersDiscovery of risk variants
    • • Dr. James Kennedy – CAMH,Toronto• Assessment of rapid PGx in primarycare setting (depression, schizophrenia)• 48 hour turnaround• Red/Yellow/Green advisory based onpanel of SNP markers (liver enzymes,drug target)• Expand to >250 primary care physicians;20,000 patients• New biomarker discovery9IMPACT StudyIndividualized Medicine: PharmacogeneticAssessment and Clinical Treatment
    • Enhanced CARE for RARE• Building on success of Finding of Rare Disease Genes in Canada(FORGE Canada) project• Identified over 100 genetic mutations underlying rare disorders in children• Reduce the “diagnostic odyssey”• International consortium• Drs. Boycott and MacKenzie – CHEO, Ottawa• Disorders are individually rare but affect ~3% of population• Enhanced CARE for RARE Genetic Diseases in Canada:• Expanded search for causative mutations in rare disorders• Identify therapeutics from pool of marketed drugs• Testing ground for evaluating genome-wide analysisas a diagnostic tool, and of the identification oftherapeutics, in small patient groups10
    • Autism Spectrum Disorders:Genomes to Outcomes• Drs. Stephen Scherer, Peter Szatmari – SickKids,Toronto• ASD affects one in 88 children, costs healthcare system $1B/yr• Early identification and intervention improves outcomes• Diagnosis difficult and slow• Objective:• WGS to identify remaining diagnostic genetic risk factors• Clinical guidelines• Early, objective diagnosis• Component of international Autism SequencingConsortium• 10,000 genomes of ASD patients and their families11
    • Top Tier HealthBioinformatics Research•Ontario is home to:•MedSavant – search for genetic variants•GeneMania – functional prediction, associationdata based on sequence•Cytoscape – visualization of complex networks•Infrastructure support•Canadahealth Infoway•eHealth12
    • Facing the Facts131. Canada is a research powerhouse“ Canada‘s science system is a success story”Richard Hawkins (University of Calgary) Lab Business Sept/Oct 2012“With less than 0.5 per cent of the world’s population, Canadaproduces 4.1 per cent of the world’s scientific papers and nearly5 per cent of the world’s most frequently cited papers.”Council of Canadian Academies “TheState of Science andTechnology in Canada, 2012”2. Canada receives a failing grade when it comes toinnovation“Despite a decade or so of innovation agendas and prosperityreports, Canada remains near the bottom of its peer group oninnovation, ranking 14th among the 17 peer countries.”Conference Board of Canada “How Canada Performs: Innovation”
    • Personalized Medicine UnfoldsLevelofexcitementInitial ideaEnthusiasmHypeReality checkDisillusionmentTrueperformanceTimeHypothesis testingDescriptive phaseSetting up
    • Challenges of ImplementingPersonalized Medicine• Integrated infrastructure to support the type of datathat will be generated and need to be shared• Resources to provide clinical validation• Privacy policy to address public concerns over datastorage and release• Education about this emerging field (both for thepublic and health professionals)• Regulatory and reimbursement policies that canaccommodate these new technologies15
    • • Large-scale innovation centre focusedon building Canada’s next generation ofgrowth companies• Provides office/lab space and resourcesincluding education, market intelligenceand business mentoring• Industries: health care, IT, cleantech,social innovation16MaRS Discovery District
    • •Commercialization agent for IP created by16 members: institutions, researchhospitals, universities•Tapping in to $1B annual R&D•20+ start-up companies; 20+ licensabletechnologies; over 100 projects indevelopmental pipeline17MaRS Innovation
    • MaRS EXCITE• MaRS Excellence in Clinical Innovation andTechnologyEvaluation (EXCITE) helps companies accelerate adoption andreimbursement of disruptive health technologies• Single, harmonized, pre-market, evidence-based process toexpedite market penetration and mitigate the risk of rejection18
    • • 20 year repository of anonymous linkedpopulation-based health information on anindividual patient basis• Unique ICES identifiers that ensure the privacyand confidentiality of health information• Unique linkage between research data andclinical data19Institute for Clinical EvaluativeServices (ICES)
    • Ontario Institute for CancerResearch• Independent not-for-profit translational cancer researchinstitute• $150M /yr funding including $82M/yr from the Government ofOntario• Supports each step in the development of important new cancerproducts, from basic research through clinical studies andregulatory approvals• Research priorities include facilitating the adoption ofpersonalized medicine for cancer• ICGC Member; OntarioTumour Bank; Informaticsand Biocomputing; High Impact ClinicalTrials;Clinical Genomics AssessmentTrial (CGAT)20
    • Ontario Brain Institute21NeuroimagingClinicalGenomicsProteomicsOtherCerebral PalsyNeurodevelopmental DisordersNeurodegenerationDepressionOther Brain DisordersData ModalitiesEpilepsy• New institute founded 2010• Two imperatives:• Integrated Discovery: science +commercialization + real-worldoutcomes• Integrated Data via Brain-CODE:open-access informatics platform• Security• Standardization• Federation• Analytics
    • • Streamline multicentre trials• Single ethical review process• Harmonized administration and platforms• Attract clinical trial investment• Demonstrate our strengths/advantages• Increase awareness at a global level• Engage public; improve patient recruitment• Increase pubic awareness of clinical trials• Establish strategies to support patientrecruitment and retention22Clinical Trials Ontario
    • What Can We Offer?A wealth of patients, investigators andplatforms geared towards the objectivesof personalized medicine23
    • What Are We Looking For?1. To understand where we sit on the“path” and push those boundaries2. Outstanding further “fundamental/discovery” science3. To develop close partnerships to helpfurther the agenda24
    • Challenges• Timing: are we ready; do we have the data?• Will personalized genome sequencing becomea driver of health care?• It is a disruptive technology – we have nomodels for implementation• Genomic data is (mostly) static but ourunderstanding of its meaning is changing rapidly• Reimbursement25
    • Top Three Recommendationsfor Achieving Tangible Results1. Integrate data2.Collect data3. Share data26
    • In Summary1. Ontario has a huge, well-funded health researchinfrastructure2. Personalized medicine is a key part of the healthsciences agenda and Ontarios infrastructure –Ontario’s health care system is well suited for PMuptake.The potential for partnering is tremendous3. Ontario faces considerable challenges bringingdiscoveries to market, especially at the level ofcommercialization.The investment opportunity ishuge27
    • 28Ontario Successes• Analytical equipment and reagents development company –developed mass cytometer for single cell analysis• Raised $14.6 million in follow on financing in 2011• Operates facility in Markham, ON and has 45 employees• Molecular diagnostic company: colorectal cancer and age-related macular degeneration• Revenues of $5.8 million in 2011 and $8 million in the firstquarter of 2012.• Secured $2.3 million in funding in the past year
    • 29Ontario Successes• Early-stage molecular diagnostics company - developingassays to help manage cancer chemotherapy• Received OGI investment to further develop and validate leadproduct, the RNA Disruption Assay™ (RDA™), which enables apersonalized approach to chemotherapy management• Raised additional $1.6 million in financing to further developtheir assay